AbbVie News Center - News
2025年1月3日 · AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings...
AbbVie to Acquire Landos Biopharma, Further Strengthening its
2024年3月25日 · NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients ...
AbbVie to Acquire ImmunoGen, including its Flagship Cancer
2023年11月30日 · ImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has the potential to be transformative across multiple solid tumors and hematologic malignancies; Transaction valued at $31.26 per share in cash, for a total equity value of approximately $10.1 billion; AbbVie to hold an investor conference call at 8:00 a.m. CT
AbbVie Announces Appointment of Robert A. Michael as Chief …
NORTH CHICAGO, Ill., Feb. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO). Mr.
AbbVie Completes Acquisition of ImmunoGen - Feb 12, 2024
2024年2月12日 · AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie's diluted EPS beginning in 2027 and significantly accretive over the long-term. Full-Year 2024 Outlook. AbbVie is reaffirming its previously issued 2024 full-year …
AbbVie Completes Acquisition of Cerevel Therapeutics
2024年8月1日 · "AbbVie's acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond," said Robert A. Michael, chief executive officer, AbbVie. "Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological ...
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
2024年2月2日 · The acquisition accelerates AbbVie's entry into the solid tumor space and enhances AbbVie's oncology pipeline through the addition of multiple promising next-generation ADCs. The transaction values ImmunoGen at a total equity value of approximately $10.1 billion .
AbbVie News Center - News
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new... More »
AbbVie to Acquire Nimble Therapeutics, Further Strengthening …
2024年12月13日 · NORTH CHICAGO, Ill. and MADISON, Wis., Dec. 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of ...
AbbVie Provides U.S. Regulatory Update on ABBV-951 ... - AbbVie …
2024年6月25日 · Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form ...